Bapineuzumab

Bapineuzumab is a humanized monoclonal antibody which acts on the nervous system and has potential therapeutic value for the treatment of Alzheimer's disease and quite possibly Glaucoma. Bapineuzumab is an antibody to the beta-amyloid (Aβ) plaques that are believed to underlie Alzheimer's disease neuropathology. Previous clinical trials for the first iteration of the drug, called AN-1792, patients with Alzheimer's disease using active immunization had positive outcomes with removal of plaques and quality of life increases, but 6% of subjects developed aseptic meningitis and the trial was stopped last decade(for a review, see Woodhouse et al. 2007 ). Bapineuzumab is currently being co-developed by the pharmaceutical companies Élan and Wyeth and has just entered Phase III trials.